# Medical Coverage Policy | Home Spirometry





**EFFECTIVE DATE:** 07/01/1999 **POLICY LAST UPDATED:** 09/17/2013

#### **OVERVIEW**

The policy documents coverage determination on home spirometry devices for the monitoring of pulmonary function in the home.

#### **PRIOR AUTHORIZATION**

Not applicable

# **POLICY STATEMENT**

BlueCHiP for Medicare and Commercial Products:

Home spirometry is considered not medically necessary as there is not sufficient published, peer-reviewed, scientific literature that demonstrates that the procedure is effective.

#### **MEDICAL CRITERIA**

None

# **BACKGROUND**

Home spirometry devices allow for the monitoring of pulmonary function in the home. Their primary proposed use is by lung transplant recipients to aid in the early diagnosis of infection and rejection. They can potentially also be used in other situations that require pulmonary function monitoring.

In the immediate post-operative period, lung transplant recipients must be carefully monitored for the development of either rejection episodes or infectious complications. Monitoring techniques include complete pulmonary function testing, serial chest x-rays, bronchioalveolar lavage, and transbronchial biopsy. Transbronchial biopsy is thought to be the only objective method of distinguishing between these 2 common complications. Transbronchial biopsy is typically performed on a routine schedule, with additional biopsies performed if the patient becomes symptomatic. Home spirometry is proposed as a technique to provide daily monitoring to promptly identify presymptomatic patients who may benefit from a diagnostic transbronchial biopsy.

Home spirometry uses battery-operated spirometers that permit regular daily measurement of pulmonary function in the home, typically forced expiratory volume in 1 second (FEV-1) and forced vital capacity (FVC). The device has been primarily investigated among lung transplant recipients as a technique to provide early diagnosis of infection and rejection. Home spirometry may also be referred to as ambulatory spirometry.

There is little published clinical data to support scientific conclusions regarding the use of home monitoring of FEV-1 and FVC. Specifically, there are inadequate data to determine how reductions in FEV-1 and FVC relate clinical symptoms, and how this information can be used to determine the necessity of transbronchial biopsies. This policy is not intended to address peak flow meters.

### **COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable Services Not Medically Necessary coverage.

# **CODING**

The following codes are not medically necessary for BlueCHiP for Medicare and Commercial products:

```
94014
94015
94016
```

### **RELATED POLICIES**

None

### **PUBLISHED**

Provider Update Nov 2013
Provider Update Jul 2012
Provider Update Sep 2011
Provider Update Oct 2010
Provider Update Jun 2009

#### **REFERENCES**

Blue Cross Blue Shield Association Medical Policy Reference Manual. Home Spirometry. 2.01.33.

### ----- CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

